Skip to main content
HairCited

Effects of dietary supplements on androgenetic alopecia: a systematic review and network meta-analysis.

Lei Zhou, Wenkang Zhu, Yan Chen
Systematic Review Frontiers in nutrition 2025
PubMed DOI PDF
<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'pmid\u003D41561175'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Loại nghiên cứu
systematic review
Cỡ mẫu
1658
Can thiệp
Effects of dietary supplements on androgenetic alopecia: a systematic review and network meta-analysis. various dietary supplements (Nutrafol, apple extract, tocotrienols, pumpkin seed oil, Cistanche/Lami
Đối chứng
Placebo
Xu hướng hiệu quả
Positive
Nguy cơ sai lệch
Moderate

Abstract

BACKGROUND: In recent years, androgenetic alopecia (AGA) has emerged as a significant public health concern due to its high prevalence and progressive nature. In addition to progressive scalp thinning and hair loss, patients often experience psychological distress and diminished quality of life. While standard treatments such as finasteride and minoxidil are effective, their side effects and adherence issues limit long-term use, making the exploration of safe and accessible intervention strategies essential. Dietary supplements, claimed to promote hair growth by inhibiting androgen pathways and improving the follicular microenvironment, have become an attractive adjunct for both clinicians and patients due to their low cost and ease of use. However, existing studies have limitations, including the diversity of supplements, small sample sizes, and the lack of direct comparisons among different supplements, making it unclear how they compare in terms of efficacy and safety. This study aims to use a network meta-analysis (NMA) to compare the effectiveness and safety of various dietary supplements based on outcomes such as hair density and terminal hair density, providing evidence-based support for clinical decision-making. METHODS: A systematic search was conducted in English-language databases such as PubMed, Cochrane Library, Embase, and Web of Science for randomized controlled trials (RCTs) investigating the use of dietary supplements for treating AGA. Stata 16.0 software was used for network meta-analysis, and Revman 5.4 software was utilized for evaluating study quality and bias risk; additionally, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework was applied to rate the certainty (quality) of evidence for the included studies. RESULTS: A total of 19 RCTs involving 1,658 AGA patients were included, with 894 patients in the supplement group and 764 in the control group. Sixteen dietary supplements were investigated. Results showed that compared with placebo, standardized plant extracts (Nutrafol), apple extract (AMSbzs, AMS), tocotrienols, pumpkin seed oil (PSO), and a compound extract of Cistanche and Laminaria (MK-R7) significantly improved hair density. Multi-component supplements (ALRV5XR), standardized plant extracts (Nutrafol), and probiotics effectively increased terminal hair density. In blind doctor assessments, PSO, capsaicin-isoflavones (CI), saw palmetto extract (ESR), Omega 3&6, Lambdapil, Nutrafol, and Multi-component supplements (AGA-P) showed higher hair regeneration scores than placebo or conventional treatments. No significant differences were found between interventions in terms of the terminal-to-vellus hair ratio. Overall, all dietary supplements were found to be well-tolerated. CONCLUSION: Dietary supplements have a positive impact on hair density, terminal hair density, and blind doctor evaluations in patients with androgenetic alopecia, with good tolerability. They may serve as beneficial adjuncts or alternatives to conventional treatments. Future large-scale, high-quality RCTs are needed to verify these findings. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251130173, Identifier CRD420251130173.

Full Text

PDF
Loading PDF...

Figures

Tables

Table 1

SupplementMain components and typical dosages
ESR① Betasitosterol (50 mg), saw palmetto extract (200 mg;), lecithin (50 mg), inositol (100 mg), phosphatidyl choline (25 mg), niacin (15 mg), biotin (100 μg); ② Dry plant extract (320 mg)
PSOCapsules (400 mg); pumpkin seed oil (oleic acid, linoleic acid, linolenic acid)
FSE-MFenugreek seed extract (300 mg), niacinamide (18 mg), pantothenic acid (6 mg), multivitamins (145 mg), zinc (5 mg)
TocotrienolMixed capsules (50 mg; 30.8% alphatocotrienol; 56.4% gammatocotrienol; 12.8% deltatocotrienol; 23 IUs alphatocopherol)
Omega 3&6Fish oil (460 mg), blackcurrant seed oil (460 mg), vitamin E (5 mg), vitamin C (30 mg), lycopene (1 mg)
MK-R7Extract of cistanche tubulosa (150 mg), extract of Laminaria japonica (50 mg)
AGA-PSerenoa repens (320 mg), Cucurbita pepo (320 mg), L-Cystine (425 mg), vitamin C, zinc
ProbioticsCapsules (5 × 109 CFU); Lactobacillus
CICapsaicin (6 mg); isoflavone (75 mg)
ViviscalVitamin C, zinc, AminoMar (shark powder and mollusk powder; 452.9 mg), horsetail extract (24.5 mg), flax seed extract (50 mg)
NutrafolCapsules of synergen complex, saw palmetto, maca, astaxanthin, curcumin, tocotrienols
AMSbzsAMS with maltodextrins (400 mg), biotin (0.20 mg), selenomethionine (80.0 μg), zinc (21.0 mg)
AMSApple extract (from chlorogenic acid, procyanidin B2)
PPT5αSaw palmetto (160 mg); pumpkin seed oil (100 mg); pomegranate extract (50 mg); zinc (10 mg); amino acids (50 mg L-cystine, 50 mg L-methionine), hydrolyzed collagen (250 mg); hyaluronic acid (25 mg), etc.
ALRV5XRCapsules (842 mg); plant extracts (Angelica sinensis, Rosmarinus officinalis, etc.), multivitamins, minerals
LambdapilL-cystine (1,000 mg), S repens (100 mg), Equisetum arvense (7.14 mg), silicon (0.50 mg), zinc (10 mg), vitamin B3 (16 mg), vitamin B5 (6 mg), vitamin B6 (1.4 mg), D-biotin (50 μg), taurine (40 mg)

Table 2

TreatmentHair densityRankFinal hair densityRankBlind assessment by doctorsRankFinal hair/soft furRank
Lambdapil46.0%5
ALRV5XR99.0%186.70%1
Probiotics20.90%951.80%378.60%2
FSE-M30.10%841.50%5
AGA-P25.60%8
Tocotrienol74.10%3
PSO52.60%573.10%2
CI71.60%3
Nutrafol81.10%180.80%238.90%73.10%5
ESR64.80%4
PPT5α18.30%6
AMS72.60%4
Viviscal35.70%745.80%4
MK-R752.30%6
AMSbzs76.60%2
Omega 3&640.30%642.60%3
Finasteride83.30%1
Placebo3.90%1012.70%76.40%939%4

Table 3

TreatmentDiarrhea (n)Flatulence (n)Itchy scalp (n)Generalized pruritus (n)Constipation (n)Loss of appetite (n)Gastrointestinal discomfort (n)Stomachache (n)
Lambdapil1
ALRV5XR1
Probiotics2
FSE-M21
PSO11
Nutrafol13
ESR1
PPT5α1
AMSbzs12
AMS32
MK-R71

Table 4

InterventionCases (n, %)Duration (days)Treatment discontinuation (yes/no)
Lambdapil1 (2.8%)NIYes
Probiotics2 (1.4%)7–14No
FSE-M3 (5.3%)3No
PSO2 (2.6%)NINo
Nutrafol4 (1.8%)NINo
ESR1 (0.8%)NINo
PPT5α1 (2.1%)NIYes
AMSbzs3 (1.2%)NINo
AMS5 (6.2%)NINo
MK-R71 (1.0%)NINo

Table 5

Certainty assessmentEffectQuality
No. of studiesDesignRisk of biasInconsistencyIndirectnessImprecisionOther considerationsEffect size (95% CI)
Hair density
10RCTSNo seriousNo seriousNo seriousNo seriousSeriousSMD = 0.52, 95% CI: 0.29, 1.32Moderate
Final hair density
7RCTSSeriousNo seriousNo seriousNo seriousSeriousSMD = 0.58, 95% CI: 0.24, 0.91Low
Blind assessment by doctors
9RCTSNo seriousSeriousNo seriousNo seriousSeriousRR = 2, 95% CI: 1.23, 3.27Low
Final hair/soft fur
5RCTSNo seriousNo seriousNo seriousSeriousNo seriousSMD = 0.14, 95% CI: −0.05, 0.34Moderate

References

  1. Untitled
  2. Untitled
  3. Untitled
  4. Untitled
  5. Untitled
  6. Untitled
  7. Untitled
  8. Untitled
  9. Untitled
  10. Untitled
  11. Untitled
  12. Untitled
  13. Untitled
  14. Untitled
  15. Untitled
  16. Untitled
  17. Untitled
  18. Untitled
  19. Untitled
  20. Untitled
  21. Untitled
  22. Untitled
  23. Untitled
  24. Untitled
  25. Untitled
  26. Untitled
  27. Untitled
  28. Untitled
  29. Untitled
  30. Untitled
  31. Untitled
  32. Untitled
  33. Untitled
  34. Untitled
  35. Untitled
  36. Untitled
  37. Untitled
  38. Untitled
  39. Untitled
  40. Untitled
  41. Untitled
  42. Untitled
  43. Untitled
  44. Untitled
  45. Untitled
  46. Untitled
  47. Untitled
  48. Untitled
  49. Untitled
  50. Untitled
  51. Untitled
  52. Untitled
  53. Untitled
  54. Untitled
  55. Untitled

Used In Evidence Reviews

Similar Papers